Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Inventory: 2018-2025

Historic Change in Inventory for Ultragenyx Pharmaceutical (RARE) over the last 8 years, with Sep 2025 value amounting to $5.6 million.

  • Ultragenyx Pharmaceutical's Change in Inventory rose 123.80% to $5.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.6 million, marking a year-over-year decrease of 19.62%. This contributed to the annual value of $11.2 million for FY2024, which is 61.72% up from last year.
  • Per Ultragenyx Pharmaceutical's latest filing, its Change in Inventory stood at $5.6 million for Q3 2025, which was up 2,789.90% from -$208,000 recorded in Q2 2025.
  • In the past 5 years, Ultragenyx Pharmaceutical's Change in Inventory ranged from a high of $5.6 million in Q3 2025 and a low of -$474,000 during Q1 2021.
  • Its 3-year average for Change in Inventory is $2.2 million, with a median of $2.1 million in 2024.
  • Its Change in Inventory has fluctuated over the past 5 years, first slumped by 218.12% in 2021, then skyrocketed by 1,782.98% in 2022.
  • Ultragenyx Pharmaceutical's Change in Inventory (Quarterly) stood at $990,000 in 2021, then soared by 324.75% to $4.2 million in 2022, then tumbled by 53.48% to $2.0 million in 2023, then rose by 25.56% to $2.5 million in 2024, then surged by 123.80% to $5.6 million in 2025.
  • Its Change in Inventory stands at $5.6 million for Q3 2025, versus -$208,000 for Q2 2025 and $763,000 for Q1 2025.